Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases worldwide. Current treatments are often associated with off-target effects and do not significantly impact disease progression. New therapies are therefore urgently needed to overcome this social burden. Glucagon-like peptide-1 (GLP-1), an incretin hormone, has been used to control T2DM symptomatology. However, the administration of peptide or proteins drugs is still a huge challenge in the pharmaceutical field, requiring administration by parenteral routes. This article reviews the main hurdles in oral administration of GLP-1 and focuses on the strategies utilized to overcome them.
ShawJESicreeRAZimmetPZ, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract.2010;87 (1): 4–14.
2.
TahraniAAPiyaMKKennedyABarnettAH, Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacol Ther.2010;125 (2): 328–61.
3.
NicholsonGHallGM, Diabetes mellitus: New drugs for a new epidemic. Br J Anaesth.2011;107 (1): 65–73.
4.
ArulmozhiDKPorthaB.GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci.2006;28 (1–2): 96–108.
5.
SadrzadehNGlembourttMJStevensonCL, Peptide drug delivery strategies for the treatment of diabetes. J Pharm Sci.2007;96 (8): 1925–54.
6.
MarreMPenfornisA.GLP-1 receptor agonists today. Diabetes Res Clin Pract.2011;93 (3): 317–27.
7.
NauckMAVardarliIDeaconCFHolstJJMeierJJ, Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?Diabetologia.2011;54 (1): 10–8.
8.
BaggioLLDruckerDJ, Biology of Incretins: GLP-1 and GIP. Gastroenterology.2007;132 (6): 2131–57.
9.
HolstJJ, The physiology of glucagon-like peptide 1. Physiol Rev.2007;87 (4): 1409–39.
10.
SteinertREPollerBCastelliMCFriedmanKHuberARDreweJBeglingerC.Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther.2009;86 (6): 644–50.
11.
SteinertREPollerBCastelliMCDreweJBeglingerC.Oral administration of glucagon-like peptide 1 or peptide YY 3–36 affects food intake in healthy male subjects. Am J Clin Nutr.2010;92 (4): 810–7.
12.
TakeiIKasataniT.Future therapy of diabetes mellitus. Biomed Pharmacother.2004;58 (10): 578–81.
13.
PorthaBTourrel-CuzinCMovassatJ.Activation of the GLP-1 receptor signalling pathway: A relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res.2011;2011: 376–509.
14.
HolstJJChristensenMLundAde HeerJSvendsenBKielgastUKnopFK, Regulation of glucagon secretion by incretins. Diabetes Obes Metab.2011;13Suppl 1: 89–94.
15.
AhrénB.GLP-1 for type 2 diabetes. Exp Cell Res.2011;317 (9): 1239–45.
16.
PerfettiRMerkelP.Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function. Eur J Endocrinol.2000;143 (6): 717–25.
17.
GallwitzB.New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud.2005;2 (2): 61–9.
18.
GutzwillerJPDreweJGökeBSchmidtHRohrerBLareidaJBeglingerC.Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol.1999;276 (5 Pt 2): R1541–4.
19.
NeumillerJJ, Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: Implications for treatment. Clin Ther.2011;33 (5): 528–76.
20.
DavidsonMH, Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol.2011;108 (3 Suppl): 33B–41B.
21.
CerneaSRazI.Therapy in the early stage: Incretins. Diabetes Care.2011;34Suppl 2: S264–71.
22.
VilsbollTKrarupTMadsbadSHolstJJ, No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med.2001;18 (2): 144–9.
23.
HolstJJDeaconCToft-NielsenMBBjerre-KnudsenL.On the treatment of diabetes mellitus with glucagon-like peptide-1. Ann N Y Acad Sci.1998;865: 336–43.
24.
UngerJ.Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc.2011;111 (2Suppl 1): eS2–9.
25.
UngerJRParkinCG, Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. Diabetes Ther.2011;2 (1): 29–39.
26.
GarberAJ, Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care.2011;34Suppl 2: S279–84.
27.
LiYZhengXTangLXuWGongM.GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. Peptides.2011;32 (6): 1303–12.
28.
DeaconCF, Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag.2009;5 (1): 199–211.
29.
KalraSKalraBKumarA.GLP-1 analogs: Newer molecules, newer uses. Recent Pat Endocr Metab Immune Drug Discov.2009;3 (2): 129–34.
30.
ChenMCSonajeKChenKJSungHW, A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials.2011;32 (36): 9826–38.
31.
BeglingerCPollerBArbitEGanzoniCGassSGomez-OrellanaIDreweJ.Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: A proof-of-concept study in healthy subjects. Clin Pharmacol Ther.2008;84 (4): 468–74.
32.
CaoXGibbsSTFangLMillerHALandowskiCPShinHCLennernasHZhongYAmidonGLYuLXSunD.Why is it challenging to predict intestinal drug absorption and oral bio-availability in human using rat model. Pharm Res.2006;23 (8): 1675–86.
33.
HammanJHDemanaPHOlivierEI, Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights.2007;2: 71–81.
34.
MahatoRINarangASThomaLMillerDD, Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst.2003;20 (2–3): 153–214.
35.
Le FerrecEChesneCArtussonPBraydenDFabreGGiresPGuillouFRoussetMRubasWScarinoML, In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Altern Lab Anim.2001;29 (6): 649–68.
36.
KrolSEllis-BehnkeRMarchettiP.Nanomedicine for treatment of diabetes in an aging population: State-of-the-art and future developments. Maturitas.2012;73 (1): 61–7.
37.
ThompsonCIbieC.The oral delivery of proteins using interpolymer polyelectrolyte complexes. Ther Deliv.2011;2 (12): 1611–31.
38.
LeeHJ, Protein drug oral delivery: The recent progress. Arch Pharm Res.2002;25 (5): 572–84.
39.
LaiSKWangYYHanesJ.Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev.2009;61 (2): 158–71.
40.
EnsignLMConeRHanesJ.Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev.2011;64 (6): 557–70.
41.
AtumaCStrugalaVAllenAHolmL.The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol.2001;280 (5): G922–9.
42.
JohanssonMELarssonJMHanssonGC, The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A.2011;108Suppl 1: 4659–65.
43.
JinYSongYZhuXZhouDChenCZhangZHuangY.Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials.2012;33 (5): 1573–82.
44.
Des RieuxAFievezVTheateIMastJPreatVSchneiderYJ, An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci.2007;30 (5): 380–91.
45.
Des RieuxAFievezVMomtazMDetrembleurCAlonso-SandeMVan GelderJCauvinASchneiderYJPréatV.Helodermin-loaded nanoparticles: Characterization and transport across an in vitro model of the follicle-associated epithelium. J Control Release.2007;118 (3): 294–302.
46.
FearnRAHirstBH, Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models. Environ Toxicol Pharmacol.2006;21 (2): 168–78.
47.
GriffinBTO'DriscollCM, Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv.2011;2 (12): 1633–53.
48.
YounYSChaeSYLeeSKwonMJShinHJLeeKC, Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: Design, preparation, and biological evaluation. Eur J Pharm Biopharm.2008;68 (3): 667–75.
49.
Salamat-MillerNJohnstonTP, Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm.2005;294 (1–2): 201–16.
50.
QiuYChenYZhangGGLiuLPorterWR, eds. Developing solid oral dosage forms: Pharmaceutical theory and practice. Burlington: Academic Press; 2009.
51.
AssimakopoulosSFPapageorgiouICharonisA.Enterocytes' tight junctions: From molecules to diseases. World J Gastrointest Pathophysiol.2011;2 (6): 123–37.
52.
KhafagyEl-SMorishitaMOnukiYTakayamaK.Current challenges in non-invasive insulin delivery systems: A comparative review. Adv Drug Deliv Rev.2007;59 (15): 1521–46.
53.
ParkKKwonICParkK.Oral protein delivery: Current status and future prospect. React Funct Polym.2011;71 (3): 280–7.
54.
MaherSBraydenDJ, Overcoming poor permeability: Translating permeation enhancers for oral peptide delivery. Drug Discov Today.2012;9 (2): e113–9.
55.
MorishitaMPeppasNA, Is the oral route possible for peptide and protein drug delivery?Drug Discov Today.2006;11 (19–20): 905–10.
56.
FontePAndradeFAraujoFAndradeCNevesJDSarmentoB.Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol.2012;508: 295–314.
57.
DeliMA, Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta.2009;1788 (4): 892–910.
58.
Cano-CebrianMJZornozaTGraneroLPolacheA.Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: A target for drug delivery. Curr Drug Deliv.2005;2 (1): 9–22.
59.
LiangJFYangVC, Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun.2005;335 (3): 734–8.
60.
ChalasaniKBRussell-JonesGJJainAKDiwanPVJainSK, Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release.2007;122 (2): 141–50.
61.
FrancisMFCristeaMWinnikFM, Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules.2005;6 (5): 2462–7.
62.
KimSKLeeEHVaishaliBLeeSLeeYKKimCYMoonHTByunY.Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release.2005;105 (1–2): 32–42.
63.
SaidHM, Intestinal absorption of water-soluble vitamins in health and disease. Biochem J.2011;437 (3): 357–72.
64.
ReidlingJCNabokinaSMSaidHM, Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: A study of the hSMVT system. Am J Physiol Gastrointest Liver Physiol.2007;292 (1): G275–81.
65.
RamanathanSPooyanSSteinSPrasadPDWangJLeibowitzMJGanapathyVSinkoPJ, Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharm Res.2001;18 (7): 950–6.
66.
SaidHM, Cell and molecular aspects of human intestinal biotin absorption. J Nutr.2009;139 (1): 158–62.
67.
JinCHChaeSYSonSKimTHUmKAYounYSLeeSLeeKC, A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release.2009;133 (3): 172–7.
68.
LeeSYounYSLeeSHByunYLeeKC, PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia.2006;49 (7): 1608–11.
69.
LeeSHLeeSYounYSNaDHChaeSYByunYLeeKC, Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem.2005;16 (2): 377–82.
70.
YounYSChaeSYLeeSJeonJEShinHGLeeKC, Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol.2007;73 (1): 84–93.
71.
YounYSJeonJEChaeSYLeeSLeeKC, PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Diabetes Obes Metab.2008;10 (4): 343–6.
72.
ChaeSYChunYGLeeSJinCHLeeESLeeKCYounYS, Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci.2009;98 (4): 1556–67.
73.
ChaeSYJinCHShinHJYounYSLeeSLeeKC, Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem.2008;19 (1): 334–41.
74.
HanatoJKuriyamaKMizumotoTDebariKHatanakaJOnoueSYamadaS.Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect. Int J Pharm.2009;382 (1–2): 111–6.
75.
GaoZTangYChenJBaiRZhangQHouYLuYBaiG.A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA micro-spheres. Peptides.2009;30 (10): 1874–81.
76.
KwakHHShimWSSonMKKimYJKimTHYounHJKangSHShimCK, Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats. Eur J Pharm Sci.2010;40 (2): 103–9.
77.
ChoiSBaudysMKimSW, Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats. Pharm Res.2004;21 (5): 827–31.
78.
YinDLuYZhangHZhangGZouHSunDZhongY.Preparation of glucagon-like peptide-1 loaded PLGA microspheres: Characterizations, release studies and bioactivities in vitro/in vivo. Chem Pharm Bull (Tokyo).2008;56 (2): 156–61.
79.
JosephJWKalitskyJSt-PierreSBrubakerPL, Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia.2000;43 (10): 1319–28.
80.
CaiGJiangH.pH-sensitive nanoparticles self-assembled from a novel class of biodegradable amphiphilic copolymers based on chitosan. J Mater Sci Mater Med.2009;20 (6): 1315–20.
81.
SonajeKLinKJWangJJMiFLChenCTJuangJHSungHW, Self-assembled pH-sensitive nanoparticles: A platform for oral delivery of protein drugs. Adv Funct Mater.2010;20 (21): 3695–700.
82.
MakhlofATozukaYTakeuchiH.Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci.2011;42 (5): 445–51.
SungHWSonajeKLiaoZXHsuLWChuangEY, pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: From mechanism to therapeutic applications. Acc Chem Res.2012;45 (4): 619–29.
85.
HePTangZLinLDengMPangXZhuangXChenX.Novel biodegradable and pH-sensitive poly(ester amide) microspheres for oral insulin delivery. Macromol Biosci.2012;12 (4): 547–56.
86.
WangXQDaiJDChenZZhangTXiaGMNagaiTZhangQ.Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release.2004;97 (3): 421–9.
87.
ChellampillaiBPawarAP, Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet.2011;35 (3–4): 123–9.
88.
NguyenHNWeySPJuangJHSonajeKHoYCChuangEYHsuCWYenTCLinKJSungHW, The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials.2011;32 (10): 2673–82.
89.
ChenDLiaoJLiNZhouCLiuQWangGZhangRZhangSLinLChenKXieXNanFYoungAAWangMW, A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A.2007;104 (3): 943–8.
90.
KnudsenLBKielDTengMBehrensCBhumralkarDKodraJTHolstJJJeppesenCBJohnsonMDde JongJCJorgensenASKercherTKostrowickiJMadsenPOlesenPHPetersenJSPoulsenFSidelmannUGSturisJTruesdaleLMayJLauJ.Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A.2007;104 (3): 937–42.
91.
LiYXuWTangLGongMZhangJ.A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. Peptides.2011;32 (7): 1408–14.
92.
TengMJohnsonMDThomasCKielDLakisJNKercherTAytesSKostrowickiJBhumralkarDTruesdaleLMayJSidelmanUKodraJTJørgensenASOlesenPHde JongJCMadsenPBehrensCPetterssonIKnudsenLBHolstJJLauJ.Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett.2007;17 (19): 5472–8.
93.
EldorRKidronMGreenberg-ShushlavYArbitE.Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol.2010;4 (6): 1516–23.
MalkovDAngeloRWangHZFlandersETangHGomez-OrellanaI.Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr Drug Deliv.2005;2 (2): 191–7.
99.
HoffmanAQadriB.Eligen insulin–a system for the oral delivery of insulin for diabetes. IDrugs.2008;11 (6): 433–41.
